A Phase III, Case Series Clinical Study of the Reversal of the Anticoagulant Effects of Dabigatran by Intravenous Administration of 5.0 g Idarucizumab (BI 655075) in Patients Treated with Dabigatran Etexilate who have Uncontrolled Bleeding or Require Emer

Project: Research project

Project Details

Effective start/end date4/6/154/6/18


  • Boehringer Ingelheim Pharmaceuticals, Inc. (Agmt 04/06/15)